Q3 2020 Sales Performance

ORR (%) bintrafusp alfa (M7824)* Encouraging clinical efficacy, pivotal study started in BTC Non small cell lung cancer (NSCLC) 2L Pembrolizumab response rates in KEYNOTE 010 and KEYNOTE 001 studies in 2L NSCLC 100% 80% 60% 44% 40% 18% 27% 18% 29% 20% 0% All PD-L1+* PD-L1 high* ■Keynote 010 Keynote 001 bintrafusp alfa response rates in 2L NSCLC 1200mg (data cut off 23 July 2018) ORR (%) 100% 80% 86% (6/7) 60% 37% 40% 25% (10/27) 20% (10/40) 0% All PD-L1+* PD-L1 high* • Durable responses across all PD-L1 expression levels in 2L NSCLC Efficacy according to independent read, RECIST 1.1 gsk Biliary tract cancer (BTC) 2L B Minor, peripheral Significant biliary duct duation... ..bifurcation biliary duet dilation Extra- hepatio tumor Intra hepatic tumor Change in Sum of Diameters (%) • Overall Response Rate (ORR) of 20% • Median Overall Survival (mOS) of 12.7 months • Benchmark 2L Chemotherapy: 5-8% ORR and 7.2 months mOS# Pembrolizumab: 5.8% ORR and 9.1 months mOS (Keynote-158)^ * PD-L1+ (pembro:22C3 TPS ≥1%; M7824: EMD001 ≥1%), PD-L1 high (pembro:22C3 TPS ≥ 50%; M7824: EMD 001 ≥ 80%; TPS ≥50% with 22C3 comparable to ≥80% with EMD 001 assessments) + Alliance with Merck KGaA, Darmstadt, Germany; # Salati et al., ASCO 2019; ^ Ueno et al., ESMO 2018 54

View entire presentation